Manufacture of Oil-in-Water Emulsion Adjuvants
Author:
- 8 October 2016
- book chapter
- Published by Springer Nature
- Vol. 1494, 165-180
Abstract
Emulsion adjuvants for human vaccines have evolved gradually over the last century. Current formulations are the result of many refinements to their composition and manufacturing, as well as optimization for safety and efficacy. Squalene has emerged as being particularly suitable for the manufacturing of safe oil-in-water (O/W) adjuvants for parenteral applications due to its biocompatibility and ability to be metabolized. Emulsion particle size has been identified as an important parameter affecting the pharmaceutical performance of O/W emulsion adjuvants. Submicronic emulsions with sizes in the 80–200 nm range are preferred for potency, manufacturing consistency, and stability reasons. Two manufacturing processes, high pressure homogenization (HPH or microfluidization) and a phase inversion temperature method (PIT), are described to yield such fine and long-term stable emulsion adjuvants.Keywords
This publication has 34 references indexed in Scilit:
- The Development of Self-Emulsifying Oil-in-Water Emulsion Adjuvant and an Evaluation of the Impact of Droplet Size on PerformanceJournal of Pharmaceutical Sciences, 2015
- Designing and building the next generation of improved vaccine adjuvantsJournal of Controlled Release, 2014
- An update on safety and immunogenicity of vaccines containing emulsion-based adjuvantsExpert Review of Vaccines, 2013
- The history of MF59 ® adjuvant: a phoenix that arose from the ashesExpert Review of Vaccines, 2013
- The mechanism of action of MF59 – An innately attractive adjuvant formulationVaccine, 2012
- Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigensVaccine, 2012
- Emulsion-based adjuvants for influenza vaccinesExpert Review of Vaccines, 2009
- Development of Vaccine Adjuvants: A Historical Perspective2006
- Squalene and Squalane Emulsions as AdjuvantsMethods, 1999
- MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines1995